Predict which pancreatic cancer patients benefit from surgery after chemotherapy

This study is testing whether combining three tools—advanced MRI scans, genetic markers in blood, and analysis of tumor DNA in the bloodstream—can better predict which patients with borderline resectable or locally advanced pancreatic cancer will successfully have their tumors removed by surgery after receiving FOLFIRINOX chemotherapy. Right now, doctors struggle to know in advance which patients will truly benefit from surgery, sometimes leading to exploratory operations that don't help. This research aims to give doctors clearer answers before surgery to avoid unnecessary procedures.

Many patients with advanced pancreatic cancer receive this medication followed by surgery, but doctors currently cannot reliably predict who will actually benefit from the operation. This leads some patients to undergo exploratory surgery that doesn't help them and may delay other important treatments. By combining multiple prediction tools, this study hopes to spare patients from unnecessary surgery and help doctors make smarter treatment decisions.